Molmed, l'Opa giapponese in bilico per golden power - ilGiornale.it
Il gioiello biotech MolMed ai giapponesi. Inizia così lo shopping a Piazza Affari - Formiche.net
Ultime Notizie Molmed News
Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases | Journal of Medicinal Chemistry
Will MolMed soon have its first Cell therapy on the Market?
Will MolMed soon have its first Cell therapy on the Market?
MolMed receives IND clearance by the FDA to conduct a Phase III trial of TK for high-risk leukaemia in the United States
COMUNICATO STAMPA
Overview of the Italian Primary Markets
MOLMED S.P.A. : MLM Stock Price | IT0001080248 | MarketScreener
MolMed: AIFA approva commercializzazione Zalmoxis. Titolo vola in Borsa - Economia e Finanza - Repubblica.it
MolMed - YouTube
MolMed now part of AGC Biologics | LinkedIn
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text
Frontiers | Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs
Molmed, Opa dei giapponesi di Agc. Per Berlusconi 30 milioni di plusvalenza - Affaritaliani.it
MolMed: Contact Details and Business Profile
MolMed - Wikipedia
Relazione sulla Remunerazione MolMed S.p.A.
Antioxidants | Free Full-Text | Cellular Aging Characteristics and Their Association with Age-Related Disorders
Small Cap Conference 2013: listed SMEs meet investors at Borsa Italiana
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text
MolMed now part of AGC Biologics | LinkedIn
Molmed, la giapponese Agc supera il 50% in Opa - Il Sole 24 ORE
